Flupentixol

  • 1 lab in 1 country
  • Funder: Novo Nordisk Fonden
  • Humans1

Associations

1

Major adverse cardiovascular events

downin humans1

1 study
  1. Flupentixol lowers the risk of major adverse cardiovascular events in humans (IRR 0.54, 95% CI 0.45 to 0.66).

    “lower for treatment with flupentixol (0.54, 95% CI 0.45 to 0.66)”

    Humanscompared with risperidone, first 30 days of treatment30 days

    Association of Selected Antipsychotic Agents With Major Adverse Cardiovascular Events and Noncardiovascular Mortality in Elderly Persons

    Journal of the American Heart Association1 Sep 2015

Latest